Kevin Rosenberg, MD
Retina Specialist · Liverpool, NYNPI 1255560157
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,985 of the $14,484 with a category attached, or 82.7%. Genentech USA, Inc. accounts for 96.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $6,326 and has fallen 95.5% since, to $282 in 2025.
Across 24 payments — averaging $603.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$14K
- Regeneron Healthcare Solutions, Inc.$399
- AbbVie$76
- AstraZeneca$43
- Astellas Pharma US Inc$21
What the payments were for
- Consulting fees$11,98583%
- Travel & lodging$1,45610%
- Food & beverage$1,0007%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 10 | $13,944 |
| Regeneron Healthcare Solutions, Inc. | 8 | $399 |
| AbbVie(2 entities) | 4 | $76 |
| AstraZeneca | 1 | $43 |
| Astellas Pharma US Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,484 in reported general payments places this provider in the 80th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 234 | $8,969 |
| Ketorolac Tromethamine | 107 | $2,229 |
| Tobramycin | 125 | $680 |
| Atropine Sulfate | 18 | $633 |
| Timolol Maleate | 77 | $496 |
| Latanoprost | 56 | $482 |
| ValacyclovirValacyclovir Hcl | 16 | $360 |
| Brimonidine Tartrate | 46 | $295 |
| Dorzolamide Hcl | 21 | $286 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $187 |
| ErythromycinErythromycin Base | 11 | $143 |
| Ofloxacin | 11 | $115 |
| Prednisone | 15 | $93 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Liverpool
- Mark BreazzanoLiverpool$30K
- Jamin BrownLiverpool$18K
- Patrick OellersLiverpool$17K
- Bryan RutledgeLiverpool$15K
- Samuel SpaldingLiverpool$15K
- Rajeev SethLiverpool$14K
- Paul HahnNanuet$238K
- Deepika MalikWoodbury$221K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.